Financial Performance - The company expects a net profit attributable to shareholders to be in the range of -130.5 million to -87 million CNY, compared to -87.13 million CNY in the same period last year [5]. - The net profit after deducting non-recurring gains and losses is projected to be between -186.5 million and -124.5 million CNY, compared to -143.46 million CNY in the previous year [5]. - The operating revenue is anticipated to be between 2.097 billion and 2.726 billion CNY, compared to 2.45665 billion CNY in the same period last year [5]. Impairment Losses - The company plans to recognize impairment losses on fixed assets and inventory totaling approximately 27 million to 41 million CNY due to signs of impairment [9]. - The company expects to recognize goodwill impairment related to the acquisition of Guilin Hengbao Health Protection Co., Ltd. in the range of 58 million to 88 million CNY [9]. Non-Recurring Items - Non-recurring gains and losses are estimated to impact the net profit attributable to shareholders by approximately 38 million to 75 million CNY, mainly from financial investment income and government subsidies [9]. Legal and Regulatory Uncertainty - The company has not yet received a ruling on the steam price arbitration case with Tangshan Wanpu Thermal Power Co., Ltd., which introduces uncertainty regarding potential liabilities and performance impact [10]. Audit Status - The financial data provided is preliminary and has not been audited by the accounting firm, but there are no discrepancies between the company and the accounting firm regarding the earnings forecast [6].
中红医疗(300981) - 2025 Q4 - 年度业绩预告